- Home
- ANVS vs GRF Comparison
ANVS vs GRF Comparison
Compare ANVS & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- GRF
- Stock Information
- Founded
- ANVS 2008
- GRF 1989
- Country
- ANVS United States
- GRF United States
- Employees
- ANVS N/A
- GRF N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- GRF Finance/Investors Services
- Sector
- ANVS Health Care
- GRF Finance
- Exchange
- ANVS Nasdaq
- GRF Nasdaq
- Market Cap
- ANVS 48.3M
- GRF 42.6M
- IPO Year
- ANVS 2020
- GRF N/A
- Fundamental
- Price
- ANVS $2.32
- GRF $10.52
- Analyst Decision
- ANVS Strong Buy
- GRF
- Analyst Count
- ANVS 4
- GRF 0
- Target Price
- ANVS $17.33
- GRF N/A
- AVG Volume (30 Days)
- ANVS 198.0K
- GRF 3.0K
- Earning Date
- ANVS 11-07-2025
- GRF 01-01-0001
- Dividend Yield
- ANVS N/A
- GRF 3.70%
- EPS Growth
- ANVS N/A
- GRF N/A
- EPS
- ANVS N/A
- GRF 1.16
- Revenue
- ANVS N/A
- GRF N/A
- Revenue This Year
- ANVS N/A
- GRF N/A
- Revenue Next Year
- ANVS N/A
- GRF N/A
- P/E Ratio
- ANVS N/A
- GRF $8.15
- Revenue Growth
- ANVS N/A
- GRF N/A
- 52 Week Low
- ANVS $1.11
- GRF $7.93
- 52 Week High
- ANVS $10.54
- GRF $10.19
- Technical
- Relative Strength Index (RSI)
- ANVS 43.70
- GRF 52.48
- Support Level
- ANVS $2.26
- GRF $10.50
- Resistance Level
- ANVS $2.51
- GRF $10.69
- Average True Range (ATR)
- ANVS 0.11
- GRF 0.11
- MACD
- ANVS 0.01
- GRF -0.02
- Stochastic Oscillator
- ANVS 35.48
- GRF 5.00
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.